Kwality Pharmaceuticals reports strong H1 FY26 with revenue up 32%

Kwality Pharmaceuticals Ltd (KPL) reported a consolidated revenue increase of 32% year-on-year, reaching ₹224 crore in H1 FY26, up from ₹170 crore in H1 FY25. This growth was attributed to robust sales in international markets and an expanded product portfolio. EBITDA also saw a significant rise of 35% year-on-year, from ₹37 crore in H1 FY25 to ₹50 crore in H1 FY26, with margins improving to 22.5%. Net profit for H1 FY26 increased to ₹26 crore from ₹17 crore in H1 FY25.

The company’s strategic initiatives, including accelerated R&D, clinical trials, and expansion of its Biologics and Oncology facilities, contributed to its strong performance. Capital expenditure and development investments during H1 FY26 were fully funded through internal accruals, with a cash surplus of approximately ₹30 crore generated.

For the quarter ended September 30, 2025, standalone total revenue stood at ₹11221.03 lakhs, with a profit after tax of ₹1411.64 lakhs. Consolidated total revenue for the same period was ₹11194.82 lakhs, and profit after tax was ₹1411.57 lakhs. The company projects continued growth momentum in Q3 FY26, with an expected revenue of around ₹140 crore.